Company intelligence / Profile preview

Lacer

Ownership: Private
Employees: ~500
Development stage: Commercial

Overview

Lacer has a long history of commercialized products in Spain and internationally. It leads the Spanish market in several segments including oral/dental hygiene and has a broad portfolio of prescription drugs and consumer health products. The company was acquired by Italfarmaco in July 2022[3][5][9].

Therapeutic areas: OtherPsychiatryCardiovascularDermatology
Modalities: Small molecules (oral and topical formulations)personal care products
Industry: Biotech

Drug pipeline

5 assets

Lacer

Commercial

Indications: Oral health

4 more assets in the full pipeline.

Request access →

Partnerships

Distribution partnerships with pharmaceutical companies; now part of the broader Italfarmaco group[1].

Beyond the preview

Go deeper on Lacer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lacer.

Explore the full profile